Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements

- Lilly is working with the Indian government to provide baricitinib donations in conjunction with the permission - Licensing collaboration builds upon Lilly's access principles and potentially speeds up the manufacturing and distribution of baricitinib to hospitalized COVID-19 patients requiring